Investigational Drug Information for Sorivudine
What is the development status for investigational drug Sorivudine?
Sorivudine is an investigational drug.
There have been 6 clinical trials for Sorivudine.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 1997.
The most common disease conditions in clinical trials are Rectal Neoplasms, HIV Infections, and Herpes Zoster. The leading clinical trial sponsors are M.D. Anderson Cancer Center, Bristol-Myers Squibb, and Genentech, Inc.
Summary for Sorivudine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,802 |
| WIPO Patent Applications | 774 |
| Japanese Patent Applications | 155 |
| Clinical Trial Progress | Phase 3 (1997-02-01) |
| Vendors | 40 |
Recent Clinical Trials for Sorivudine
| Title | Sponsor | Phase |
|---|---|---|
| Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles) | aRigen Pharmaceuticals, Inc. | Phase 2 |
| Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | Genentech, Inc. | Phase 1 |
| Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | M.D. Anderson Cancer Center | Phase 1 |
Clinical Trial Summary for Sorivudine
Top disease conditions for Sorivudine
Top clinical trial sponsors for Sorivudine
US Patents for Sorivudine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Sorivudine Development Update, Patent Status, Regulatory History, and Market Projection
Sorivudine is not an active drug-development candidate. The oral antiviral was approved in Japan for herpes zoster in 1993, withdrawn within months after fatal interactions with fluoropyrimidine chemotherapy, and abandoned as a commercial product. It has no current FDA approval, no Orange Book listing, no established U.S. or European development program, and no credible near-term market opportunity. Any current market projection is therefore effectively zero unless a sponsor undertakes a new clinical, formulation, and regulatory program.
What is the current development status of sorivudine?
Sorivudine development is discontinued.
Sorivudine, also known as BV-araU or bromovinyl arabinosyl uracil, is a nucleoside analogue with antiviral activity against varicella-zoster virus and herpes simplex virus. The product was developed in Japan for herpes zoster and marketed under the name Usevir. Japan approved sorivudine in 1993, but the product was withdrawn after reports of severe and fatal toxicity in patients receiving concurrent fluoropyrimidine therapy.
The central safety issue was pharmacokinetic interaction. Sorivudine inhibited the metabolism of 5-fluorouracil and related compounds, including tegafur, through inhibition of dihydropyrimidine dehydrogenase activity. This caused excessive fluorouracil exposure, severe bone-marrow suppression, and deaths in patients who had received both treatments (Diasio, 1998).
| Development item | Status |
|---|---|
| Active ingredient | Sorivudine, BV-araU |
| Primary indication | Herpes zoster |
| Original sponsor or developer | Japanese pharmaceutical development program associated with Nippon Shoji and Yamasa |
| Japan approval | 1993 |
| Commercial launch | Japan, 1993 |
| Withdrawal | 1993 |
| U.S. approval | None identified |
| European approval | No active marketing authorization |
| Current clinical trials | No active late-stage program identified |
| Current commercial product | None |
| Development status | Discontinued |
When did sorivudine lose exclusivity?
Sorivudine’s commercial exclusivity is no longer relevant because the product was withdrawn decades before a conventional global launch. Any original composition-of-matter or pharmaceutical-use patents would have expired or become commercially immaterial by 2026, assuming ordinary patent terms and no surviving enforceable extensions.
The key commercial event was not generic entry. It was regulatory and market withdrawal following postmarketing safety reports. Sorivudine therefore did not progress through the standard lifecycle of a successful branded antiviral followed by an authorized generic or Paragraph IV challenge.
Sorivudine exclusivity timeline
| Year | Event |
|---|---|
| Before 1993 | Clinical development and Japanese regulatory review |
| 1993 | Japanese approval and launch for herpes zoster |
| Late 1993 | Fatal fluoropyrimidine interaction cases reported |
| 1993 | Product withdrawal from the Japanese market |
| 1990s onward | Development discontinued outside Japan |
| 2026 | No active commercial exclusivity or development program |
What patents protect sorivudine?
No commercially material, active sorivudine patent estate is publicly associated with a current product.
The original patent portfolio likely covered one or more of the following:
- Sorivudine composition of matter.
- Nucleoside analogue synthesis.
- Pharmaceutical formulations.
- Antiviral treatment methods.
- Dosing for herpesvirus infections.
Those categories would have been relevant during development. They do not create a current market barrier. Patent terms for patents filed during the original development period would generally have ended by now. The absence of an active marketed product also eliminates much of the practical value of formulation or method-of-use claims.
How strong is the sorivudine patent estate?
The historical estate may have been commercially meaningful before launch, but its present strength is negligible for three reasons:
- The original product was withdrawn.
- Core patent terms would have expired.
- The main commercial risk is safety, not freedom to operate.
A new sponsor would not obtain meaningful protection merely by reviving the original molecule. Patentability would depend on a genuinely novel formulation, dosing regimen, combination, prodrug, delivery system, or manufacturing process. Even then, regulatory authorities would require a new safety assessment addressing the fluoropyrimidine interaction.
What is the FDA regulatory status of sorivudine?
Sorivudine has no U.S. Food and Drug Administration approval identified in the public drug-approval record.
It is not an FDA-approved treatment for herpes zoster, herpes simplex infection, or any other indication. The FDA has not established a U.S. reference product for an abbreviated new drug application based on sorivudine.
What is the Orange Book status of sorivudine?
Sorivudine has no identified Orange Book listing.
The absence of an Orange Book reference product means:
- No current U.S. listed-drug patent certifications are expected.
- No active Paragraph IV dispute is associated with sorivudine.
- No authorized generic pathway exists.
- A future U.S. sponsor would likely pursue a full new drug application rather than rely on an ANDA against a marketed reference product.
Were there Paragraph IV challenges to sorivudine?
No material Paragraph IV litigation is identified.
Paragraph IV certification applies to abbreviated applications referencing an FDA-approved drug with listed patents. Sorivudine never established that U.S. regulatory foundation. Its withdrawal in Japan also removed the commercial incentive for generic firms to pursue a U.S. filing strategy.
A future sponsor seeking approval would face a full clinical and regulatory program. It could not rely on the ordinary generic substitution model used for an active, FDA-approved antiviral.
What caused sorivudine’s withdrawal?
Sorivudine caused fatal toxicity when administered near the time of fluoropyrimidine treatment.
The interaction was associated with patients receiving 5-fluorouracil or tegafur-containing therapy. Sorivudine impaired fluorouracil breakdown, increasing exposure and producing severe toxicity, including leukopenia and neutropenia. Reported deaths led to withdrawal from the Japanese market shortly after launch (Diasio, 1998; Hori et al., 1993).
The event remains one of the most important historical examples of a clinically significant drug-drug interaction involving fluoropyrimidine metabolism. It also influenced later attention to dihydropyrimidine dehydrogenase and fluorouracil pharmacology.
What safety barrier would a revived sorivudine program face?
A revival program would need to address:
- Concomitant use with 5-fluorouracil.
- Concomitant use with tegafur and other fluoropyrimidine prodrugs.
- Effects on dihydropyrimidine dehydrogenase.
- Residual toxicity after drug discontinuation.
- Prescribing controls and contraindications.
- Medication reconciliation in oncology patients.
- Potential interaction with oral fluoropyrimidine regimens.
- Risk-management requirements for herpes zoster patients with active cancer treatment.
A prominent boxed warning or strict contraindication would be likely if the interaction could not be eliminated pharmacologically. That risk would materially reduce commercial adoption even if antiviral efficacy were confirmed.
What formulations are protected by sorivudine patents?
No active formulation franchise is associated with sorivudine.
The historical product was an oral antiviral. Publicly available development history does not establish a current extended-release, topical, injectable, long-acting, or targeted-delivery formulation program.
A new formulation could theoretically be designed to reduce systemic exposure or limit interaction risk. Such an approach would require evidence that the formulation preserves antiviral activity while avoiding clinically meaningful inhibition of fluoropyrimidine metabolism. A reformulation would not automatically avoid the need for new clinical trials.
Potentially differentiating formulations could include:
| Formulation concept | Commercial rationale | Principal barrier |
|---|---|---|
| Short-course oral tablet | Direct replacement for historical use | Interaction and systemic safety |
| Topical formulation | Lower systemic exposure | Likely inadequate treatment of disseminated or severe zoster |
| Controlled-release oral product | Exposure management | May prolong interaction risk |
| Prodrug | Improved tolerability or selectivity | New toxicology and clinical development |
| Local delivery system | Reduced systemic exposure | Limited applicability in herpes zoster |
How does sorivudine compare with current herpes zoster antivirals?
Sorivudine has no practical competitive position against established agents.
| Drug | Current role | Regulatory position | Commercial position |
|---|---|---|---|
| Acyclovir | Established treatment for herpesvirus infections | Broad global approvals | Generic and low-cost |
| Valacyclovir | Oral prodrug with improved convenience | Broad global approvals | Mature branded-generic market |
| Famciclovir | Oral antiviral for herpes zoster and herpes simplex | Broad global approvals | Mature generic market |
| Brivudine | Used in some countries for herpes zoster | Geographic availability varies | Restricted by interaction concerns |
| Sorivudine | Withdrawn historical product | No current U.S. approval | No active market |
Brivudine is the closest historical comparator because it also has antiviral activity against varicella-zoster virus and can interact dangerously with fluoropyrimidines. That comparison works against sorivudine: physicians already have established antivirals, while the interaction class has a negative safety history.
Which companies are challenging sorivudine?
No active generic, biosimilar, or branded competitor is challenging sorivudine because there is no current approved sorivudine product to challenge.
The relevant competitive set consists of manufacturers of acyclovir, valacyclovir, famciclovir, and, in selected markets, brivudine. These products compete for herpes zoster treatment without requiring a sponsor to revive sorivudine’s historical safety profile.
Biosimilar competition is not applicable. Sorivudine is a small molecule, not a biologic, and no biosimilar pathway applies.
What litigation and settlement agreements affect sorivudine?
No active patent litigation or settlement agreement with material commercial effect has been identified.
The principal legal and regulatory consequences arose from adverse-event investigations and product withdrawal rather than generic patent litigation. The historical safety episode also created potential civil liability exposure for manufacturers and healthcare providers, but it did not generate a current commercial dispute comparable to modern Orange Book litigation.
What is the market projection for sorivudine?
The base-case market projection is zero through the medium term.
| Scenario | Probability profile | Market implication |
|---|---|---|
| No redevelopment | Base case | No product revenue |
| Academic or historical research only | Possible | No commercial revenue |
| New formulation program | Low | Limited opportunity after lengthy development |
| Full clinical revival | Very low | Requires major capital and safety investment |
| Successful relaunch | Remote | Could target niche herpes zoster use, but would face generic competition |
A successful relaunch would need to compete against low-cost generic acyclovir, valacyclovir, and famciclovir. The commercial opportunity would be constrained by:
- The availability of effective generic therapies.
- The short treatment duration for herpes zoster.
- Physician awareness of the historical fatal interaction.
- A narrow ability to prescribe the drug in oncology patients.
- High regulatory and pharmacovigilance costs.
- Limited value from a molecule whose primary historical advantage was antiviral potency rather than a clearly differentiated delivery profile.
Revenue exposure for current pharmaceutical companies is effectively zero because no active product franchise has been identified. There is no current branded revenue base, no observable prescription market, and no credible near-term launch forecast.
What manufacturing and intellectual-property barriers would affect redevelopment?
Manufacturing is unlikely to be the primary barrier. Sorivudine is a synthetic small molecule, so production would generally be more straightforward than manufacturing a biologic or complex cell-and-gene therapy.
The main barriers would be clinical and regulatory:
- Reproducing antiviral benefit against currently treated herpes zoster populations.
- Demonstrating a clinically acceptable interaction profile.
- Establishing whether the compound offers value over generic alternatives.
- Building a modern pharmacovigilance system.
- Securing new intellectual property with a term long enough to support investment.
- Funding global development for a mature, price-sensitive indication.
A new process patent could protect manufacturing improvements, but it would not by itself create a durable market position. A new formulation or prodrug patent could be more valuable, provided the product demonstrated a clear safety or adherence advantage.
What generic launch risks exist for a revived sorivudine product?
A revived sorivudine product would face generic competition from established alternatives rather than direct sorivudine generics.
The launch risk would be high because prescribers can substitute acyclovir, valacyclovir, or famciclovir without waiting for a new product. If a sponsor secured new patents on a formulation or dosing regimen, those rights could delay direct copying but would not prevent therapeutic substitution.
The commercial launch would also face a safety-labeling problem. A drug associated with fatal fluoropyrimidine interactions would need clear prescribing restrictions, electronic alerts, oncology-system integration, and postmarket monitoring.
Key Takeaways
- Sorivudine development is discontinued.
- The drug was approved in Japan in 1993 and withdrawn the same year after fatal interactions with fluoropyrimidine chemotherapy.
- Sorivudine has no current FDA approval and no Orange Book listing.
- No active Paragraph IV litigation, biosimilar program, or generic challenge is associated with the molecule.
- Original patent protection is no longer commercially material.
- Current market revenue is effectively zero.
- A revival would require a new clinical and regulatory program, not a conventional generic filing.
- Generic acyclovir, valacyclovir, and famciclovir create a strong commercial substitute set.
- The main redevelopment barrier is safety, particularly inhibition of fluorouracil metabolism.
FAQs
Is sorivudine still available in Japan?
No. Sorivudine was withdrawn from the Japanese market after postmarketing reports of fatal fluoropyrimidine interactions.
Can sorivudine be approved through the FDA 505(b)(2) pathway?
A sponsor could potentially evaluate a 505(b)(2) strategy, but the historical safety issue and absence of a current U.S. reference product would make a full safety and efficacy package likely necessary in practice.
Is sorivudine related to brivudine?
Yes. Both are bromovinyl nucleoside analogues with activity against varicella-zoster virus. Both have important interaction concerns involving fluoropyrimidine chemotherapy.
Does sorivudine have a biosimilar competitor?
No. Sorivudine is a small-molecule antiviral, so biosimilar regulation does not apply.
Could a new sorivudine prodrug receive fresh patent protection?
Potentially, if the prodrug were novel, non-obvious, manufacturable, and clinically differentiated. A new patent would not remove the need to establish a safe interaction profile and superior commercial value.
References
Diasio, R. B. (1998). Sorivudine and 5-fluorouracil: A clinically significant drug interaction. Clinical Pharmacokinetics, 34(2), 133-142.
Hori, S., Koto, M., & Nakayama, K. (1993). Fatal interaction between sorivudine and 5-fluorouracil derivatives. The Lancet, 342(8883), 1192-1193.
National Center for Biotechnology Information. (2024). Sorivudine. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
More… ↓
